A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis

From National Research Council Canada

Alternative title	SARS-CoV-2 and COVID-19 in Canada
Download	View final version: A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis (PDF, 3 MB) View accepted manuscript: A Canadian perspective on severe acute respiratory syndrome coronavirus 2 infection and treatment: how prevalent underlying inflammatory disease contributes to pathogenesis (PDF, 1 MB)
DOI	Resolve DOI: https://doi.org/10.1139/bcb-2020-0341
Author	Search for: Willows, Steven Derald¹; Search for: Alam, Syed Benazir¹; Search for: Sandhu, Jagdeep K.²; Search for: Kulka, Marianna¹
Name affiliation	National Research Council of Canada. Nanotechnology National Research Council of Canada. Human Health Therapeutics
Format	Text, Article
Journal title	Biochemistry and Cell Biology
ISSN	0829-8211 1208-6002
Article number	bcb-2020-0341
Physical description	75 p.
Subject	Canada; COVID-19; coronavirus; inflammation; therapeutics; chronic disease
Abstract	The coronavirus disease 2019 (COVID-19), a serious respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a global pandemic. Canada reported its first case of COVID-19 on 25th January 2020. By March 2020 the virus had spread within Canadian communities reaching the most frail and vulnerable elderly population in long-term care facilities. The majority of cases were reported in the provinces of Quebec, Ontario, Alberta and British Columbia and the highest mortality was seen among individuals aged 65 years or older. Canada has the highest prevalence and incidence rates of several chronic inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease and Parkinson’s disease. Many elderly Canadians also live with comorbid medical illnesses, such as hypertension, diabetes, cardiovascular disease and chronic lung disease and are more likely to suffer from severe COVID-19 with a poor prognosis. It is becoming increasingly evident that underlying inflammatory disease contributes to SARS-CoV-2 pathogenesis. Here, we review the mechanisms of SARS-CoV-2 infection and the host inflammatory responses that lead to resolution or progression to severe COVID-19 disease. Furthermore, we discuss the landscape of COVID-19 therapeutics that are currently in development in Canada.
Publication date	2020-10-07
Publisher	Canadian Science Publishing
Licence	Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/
Language	English
In press	Yes
Peer reviewed	Yes
NRC number	NRC-NANO-80
Export citation	Export as RIS
Report a correction	Report a correction
Record identifier	722b7ea8-6534-4c92-9e43-e1af880e59ba
Record created	2021-01-27
Record modified	2021-04-06

Report a problem on this page

Date modified:: 2021-04-18